Reference health
Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?
94/94 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
3 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 94 checked references that resolve
resolves10.1371/journal.ppat.1000642
A Neutralizing Human Monoclonal Antibody Protects against Lethal Disease in a New Ferret Model of Acute Nipah Virus Infection
resolves10.1016/j.vaccine.2013.01.025
Monoclonal antibodies for prophylactic and therapeutic use against viral infections
resolves10.1073/pnas.1220019110
Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody
resolves10.1186/1741-7015-11-4
Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases
resolves10.1038/nature13777
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp
resolves10.1155/2013/838491
Possible Future Monoclonal Antibody (mAb)-Based Therapy against Arbovirus Infections
resolves10.1371/journal.ppat.1003157
Therapeutic Efficacy of Antibodies Lacking FcγR against Lethal Dengue Virus Infection Is Due to Neutralizing Potency and Blocking of Enhancing Antibodies
resolves10.1038/ni.3058
A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus
resolves10.1016/j.cell.2015.01.031
Mechanism of Human Antibody-Mediated Neutralization of Marburg Virus
resolves10.1371/journal.pone.0128823
Characterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop
resolves10.1128/JVI.03014-14
A Novel Humanized Antibody Neutralizes H5N1 Influenza Virus via Two Different Mechanisms
resolves10.1089/aid.2014.0235
Exploring the Potential of Monoclonal Antibody Therapeutics for HIV-1 Eradication
resolves10.1038/nature13601
Broad and potent HIV-1 neutralization by a human antibody that binds the gp41–gp120 interface
resolves10.1038/nri3516
Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning
resolves10.1038/nature12744
Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys
resolves10.1126/scitranslmed.3009512
Broadly neutralizing antibodies abrogate established hepatitis C virus infection
resolves10.1016/j.virol.2012.10.007
New generation humanized mice for virus research: Comparative aspects and future prospects
resolves10.1016/j.jim.2014.02.011
Generation of improved humanized mouse models for human infectious diseases
resolves10.1084/jem.20141050
Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants
resolves10.1038/nri3311
Humanized mice for immune system investigation: progress, promise and challenges
resolves10.1128/JVI.64.4.1648-1656.1990
Neurodegenerative disease induced by the wild mouse ecotropic retrovirus is markedly accelerated by long terminal repeat and gag-pol sequences from nondefective Friend murine leukemia virus
resolves10.1128/JVI.79.10.6272-6280.2005
Induction of Long-Term Protective Antiviral Endogenous Immune Response by Short Neutralizing Monoclonal Antibody Treatment
resolves10.1128/JVI.01970-07
Endogenous Cytotoxic T-Cell Response Contributes to the Long-Term Antiretroviral Protection Induced by a Short Period of Antibody-Based Immunotherapy of Neonatally Infected Mice
resolves10.1371/journal.ppat.1000948
A Crucial Role for Infected-Cell/Antibody Immune Complexes in the Enhancement of Endogenous Antiviral Immunity by Short Passive Immunotherapy
resolves10.1128/JVI.00568-10
Long-Lasting Protective Antiviral Immunity Induced by Passive Immunotherapies Requires both Neutralizing and Effector Functions of the Administered Monoclonal Antibody
resolves10.1182/blood-2012-06-432153
Control of regulatory T cells is necessary for vaccine-like effects of antiviral immunotherapy by monoclonal antibodies
resolves10.1128/JVI.78.11.5983-5995.2004
Passive Immunotherapy in Simian Immunodeficiency Virus-Infected Macaques Accelerates the Development of Neutralizing Antibodies
resolves10.1128/JVI.00145-09
Polyfunctional CD4
<sup>+</sup>
T-Cell Induction in Neutralizing Antibody-Triggered Control of Simian Immunodeficiency Virus Infection
resolves10.1371/journal.pone.0000540
Post-Infection Immunodeficiency Virus Control by Neutralizing Antibodies
resolves10.1128/JVI.77.1.10-24.2003
Evidence for Antibody-Mediated Enhancement of Simian Immunodeficiency Virus (SIV) Gag Antigen Processing and Cross Presentation in SIV-Infected Rhesus Macaques
resolves10.1038/nm.2233
Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques
resolves10.1128/JVI.00049-13
Neutralizing Polyclonal IgG Present during Acute Infection Prevents Rapid Disease Onset in Simian-Human Immunodeficiency Virus SHIV
<sub>SF162P3</sub>
-Infected Infant Rhesus Macaques
resolves10.1038/nature14411
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
resolves10.1371/journal.pone.0018207
An Anti-HIV-1 V3 Loop Antibody Fully Protects Cross-Clade and Elicits T-Cell Immunity in Macaques Mucosally Challenged with an R5 Clade C SHIV
resolves10.1128/JVI.01503-14
Prophylaxis with a Respiratory Syncytial Virus (RSV) Anti-G Protein Monoclonal Antibody Shifts the Adaptive Immune Response to RSV rA2-line19F Infection from Th2 to Th1 in BALB/c Mice
resolves10.1128/JVI.00413-11
Multiple Functional Domains and Complexes of the Two Nonstructural Proteins of Human Respiratory Syncytial Virus Contribute to Interferon Suppression and Cellular Location
resolves10.1126/scitranslmed.3002901
A Neutralizing Human Monoclonal Antibody Protects African Green Monkeys from Hendra Virus Challenge
resolves10.1126/scitranslmed.3008929
Therapeutic Treatment of Nipah Virus Infection in Nonhuman Primates with a Neutralizing Human Monoclonal Antibody
resolves10.1016/j.antiviral.2013.06.012
A treatment for and vaccine against the deadly Hendra and Nipah viruses
resolves10.1016/j.cell.2015.03.030
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
resolves10.1073/pnas.1312772110
Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1)
resolves10.1371/journal.ppat.1003856
Enhancing Virus-Specific Immunity In Vivo by Combining Therapeutic Vaccination and PD-L1 Blockade in Chronic Hepadnaviral Infection
resolves10.1371/journal.pone.0039179
PD-1 Blockage Reverses Immune Dysfunction and Hepatitis B Viral Persistence in a Mouse Animal Model
resolves10.1371/journal.pone.0077780
PD-1 Blockade in Chronically HIV-1-Infected Humanized Mice Suppresses Viral Loads
resolves10.1371/journal.ppat.1003798
Combining Regulatory T Cell Depletion and Inhibitory Receptor Blockade Improves Reactivation of Exhausted Virus-Specific CD8+ T Cells and Efficiently Reduces Chronic Retroviral Loads
resolves10.1016/j.jhep.2014.07.005
Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation
resolves10.1089/aid.2012.0320
Augmentation of Hepatitis B Virus-Specific Cellular Immunity with Programmed Death Receptor-1/Programmed Death Receptor-L1 Blockade in Hepatitis B Virus and HIV/Hepatitis B Virus Coinfected Patients Treated with Adefovir
resolves10.1371/journal.pone.0063818
A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection
resolves10.1111/j.1600-065X.2011.01062.x
OX40:OX40L axis: emerging targets for improving poxvirus‐based CD8<sup>+</sup> T‐cell vaccines against respiratory viruses
resolves10.4049/jimmunol.1300453
Targeting CD137 Enhances Vaccine-Elicited Anti–Respiratory Syncytial Virus CD8+ T Cell Responses in Aged Mice
resolves10.4049/jimmunol.1100077
4-1BB Signaling Synergizes with Programmed Death Ligand 1 Blockade To Augment CD8 T Cell Responses during Chronic Viral Infection
resolves10.3389/fimmu.2012.00332
Targeting 4-1BB (CD137) to enhance CD8 T cell responses with poxviruses and viral antigens
resolves10.1128/JVI.03309-13
Toll-Like Receptor 7/8 (TLR7/8) and TLR9 Agonists Cooperate To Enhance HIV-1 Envelope Antibody Responses in Rhesus Macaques
resolves10.1186/1479-5876-11-25
High efficacy of CpG-ODN, Cetuximab and Cisplatin combination for very advanced ovarian xenograft tumors
resolves10.1016/j.cell.2014.07.043
Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice
resolves10.1016/j.cell.2014.08.023
Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity
resolves10.1038/nm.3443
Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo
resolves10.1016/j.virol.2011.03.012
Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals
resolves10.1038/nature06106
Fc receptor but not complement binding is important in antibody protection against HIV
resolves10.1128/JVI.00491-12
A Nonfucosylated Variant of the anti-HIV-1 Monoclonal Antibody b12 Has Enhanced FcγRIIIa-Mediated Antiviral Activity
<i>In Vitro</i>
but Does Not Improve Protection against Mucosal SHIV Challenge in Macaques
resolves10.1093/jb/mvj157
Fucose Removal from Complex-Type Oligosaccharide Enhances the Antibody-Dependent Cellular Cytotoxicity of Single-Gene–Encoded Bispecific Antibody Comprising of Two Single-Chain Antibodies Linked to the Antibody Constant Region
resolves10.1016/j.jim.2005.08.009
IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides
resolves10.1073/pnas.1108360108
Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant
resolves10.1097/QAD.0000000000000444
Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function
resolves10.1172/JCI65708
Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity
resolves10.2174/13892002113149990099
Neonatal Fc Receptor and its Role in the Absorption, Distribution, Metabolism and Excretion of Immunoglobulin G-Based Biotherapeutics
resolves10.3389/fimmu.2014.00664
Regulation of Immune Responses by the Neonatal Fc Receptor and Its Therapeutic Implications
resolves10.1038/nature13612
Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
resolves10.1097/QAD.0b013e32835cb720
Isotype-switched immunoglobulin G antibodies to HIV Gag proteins may provide alternative or additional immune responses to ‘protective’ human leukocyte antigen-B alleles in HIV controllers
resolves10.1126/scitranslmed.3007736
Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines
resolves10.1126/scitranslmed.3007730
Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination
resolves10.1371/journal.pone.0087572
Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection
resolves10.3109/10428194.2012.762512
Correlation of Fc-γ RIIA polymorphisms with latent Epstein–Barr virus infection and latent membrane protein 1 expression in patients with low grade B-cell lymphomas
resolves10.1002/hep.22337
Hepatitis C virus–infected hepatocytes extrinsically modulate dendritic cell maturation to activate T cells and natural killer cells†
The 3 references without a DOI — listed, not checked
no DOI — not checkedAntibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology
no DOI — not checkedOf mice and men: the need for humanized mouse models to study human IgG activity in vivo
no DOI — not checkedhumanized mice to study FcgammaR function
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1016/j.tim.2015.07.005"><img src="https://citestamp.com/citestamped/10.1016/j.tim.2015.07.005/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1016/j.tim.2015.07.005)